Evidence map›Paper›PMID 26134617›Full record

ArticleMolecular cancer2015

Significance of filamin A in mTORC2 function in glioblastoma.

Naphat Chantaravisoot, Piriya Wongkongkathep, Joseph A Loo, Paul S Mischel, Fuyuhiko Tamanoi

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Tumor suppressive effect of low-frequency repetitive transcranial magnetic stimulation on glioblastoma progression.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. mTOR Signaling Components in Tumor Mechanobiology.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Naphat ChantaravisootDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, 90095, USA.
Piriya WongkongkathepDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA, 90095, USA.
Joseph A LooDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA, 90095, USA.
Paul S MischelLudwig Institute for Cancer research, University of California, San Diego, CA, 92093, USA.
Fuyuhiko TamanoiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, 90095, USA. fuyut@microbio.ucla.edu.
University of California, Los Angeles · USLudwig Cancer Research · US

Funding

STRUCTURAL &FUNCTIONAL ANALYSES OF YEAST RAS PROTEINSR01CA041996 · NCI · UNIVERSITY OF CHICAGO · PI TAMANOI, FUYUHIKO · 1985 to 2014
$4.6M
The role of mTORC2 in reprogramming cancer cell metabolismR01NS073831 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MISCHEL, PAUL S · 2011 to 2020
$3.4M
UV Laser for Photodissociation-Mass Spectrometry of Proteins and Protein ComplexesR01GM103479 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LOO, JOSEPH A · 2012 to 2021
$3.2M
NCI NIH HHS R01 CA041996NCI NIH HHS R01CA41996NIGMS NIH HHS R01 GM103479NIGMS NIH HHS R01GM103479NINDS NIH HHS R01 NS073831
6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM) is one of the most highly metastatic cancers. GBM has been associated with a high level of the mechanistic target of rapamycin complex 2 (mTORC2) activity. We aimed to observe roles of mTORC2 in GBM cells especially on actin cytoskeleton reorganization, cell migration and invasion, and further determine new important players involved in the regulation of these cellular processes.

methodsTo further investigate the significance of mTORC2 in GBM, we treated GBM cells with PP242, an ATP-competitive inhibitor of mTOR, and used RICTOR siRNA to knock down mTORC2 activity. Effects on actin cytoskeleton, focal adhesion, migration, and invasion of GBM cells were examined. To gain insight into molecular basis of the mTORC2 effects on cellular cytoskeletal arrangement and motility/invasion, we affinity purified mTORC2 from GBM cells and identified proteins of interest by mass spectrometry. Characterization of the protein of interest was performed.

resultsIn addition to the inhibition of mTORC2 activity, we demonstrated significant alteration of actin distribution as revealed by the use of phalloidin staining. Furthermore, vinculin staining was altered which suggests changes in focal adhesion. Inhibition of cell migration and invasion was observed with PP242. Two major proteins that are associated with this mTORC2 multiprotein complex were found. Mass spectrometry identified one of them as Filamin A (FLNA). Association of FLNA with RICTOR but not mTOR was demonstrated. Moreover, in vitro, purified mTORC2 can phosphorylate FLNA likewise its known substrate, AKT. In GBM cells, colocalization of FLNA with RICTOR was observed, and the overall amounts of FLNA protein as well as phosphorylated FLNA are high. Upon treatments of RICTOR siRNA or PP242, phosphorylated FLNA levels at the regulatory residue (Ser2152) decreased. This treatment also disrupted colocalization of Actin filaments and FLNA.

conclusionsOur results support FLNA as a new downstream effector of mTORC2 controlling GBM cell motility. This new mTORC2-FLNA signaling pathway plays important roles in motility and invasion of glioblastoma cells.

Indexed as

Actin CytoskeletonCarrier ProteinsCell AdhesionCell Line, TumorCell MovementEnzyme ActivationFilaminsGlioblastomaHumansIndolesMechanistic Target of Rapamycin Complex 2Multiprotein ComplexesPhosphorylationProtein BindingPurinesRapamycin-Insensitive Companion of mTOR ProteinCarrier ProteinsFilaminsIndolesMechanistic Target of Rapamycin Complex 2Multiprotein ComplexesPP242PurinesRapamycin-Insensitive Companion of mTOR ProteinRICTOR protein, humanTOR Serine-Threonine Kinases

Identifiers

PMID26134617
PMCPMC4489161
OpenAlexW2136457617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.